EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer - Nico van Zandwijk; Alexandre Mathy; Lucie Boerrigter; Henrique J. Ruijter; Ivon H. G. Tielen; Daniëlle de Jong; Paul Baas; Sjaak A. Burgers; Petra M. Nederlof (2006)